SCHEMBL3595022

SCHEMBL3595022

O=C(Cn1ccc2ccccc21)NCCNCC1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.55
LMNA P02545 2/20 0.55
TP53 P04637 1/20 0.55
TSHR P16473 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MTNR1A P48039 2/20 0.50
MTNR1B P49286 2/20 0.50
NPY5R Q15761 1/20 0.50
CCNE1 P24864 1/20 0.48
CDK2 P24941 1/20 0.48
CDK5 Q00535 1/20 0.48
KMT2A Q03164 1/20 0.47
IDO1 P14902 1/20 0.47
MAPK1 P28482 3/20 0.46
ALDH1A1 P00352 1/20 0.46
SLC6A4 P31645 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
EPHX2 P34913 1/20 0.43
NTSR1 P30989 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598451 0.86 ALDH1A1 (0.45) HSD17B10LMNATP53TSHRSMN1; SMN2
SCHEMBL3608127 0.85 ALDH1A1 (0.49) HSD17B10LMNATP53TSHRSMN1; SMN2
SCHEMBL3591062 0.84 KDM4E (0.47) HSD17B10LMNATP53TSHRSMN1; SMN2
SCHEMBL3605907 0.83 ALDH1A1 (0.40) HSD17B10LMNATP53TSHRSMN1; SMN2
SCHEMBL3603868 0.82 ADORA2A (0.41) HSD17B10LMNATSHRSMN1; SMN2NPY5R
SCHEMBL3598310 0.82 NPC1 (0.46) HSD17B10LMNATP53TSHRSMN1; SMN2
SCHEMBL3585615 0.82 ALDH1A1 (0.41) HSD17B10LMNATP53TSHRSMN1; SMN2
SCHEMBL3591246 0.82 LMNA (0.46) HSD17B10LMNATP53TSHRSMN1; SMN2
SCHEMBL3601868 0.82 BACE1 (0.47) HSD17B10LMNATSHRMAPK1ALDH1A1
SCHEMBL3593043 0.82 ALDH1A1 (0.41) HSD17B10LMNATP53TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 HSD17B10 3413/4885LMNA 4638/4885TP53 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.